Details

Autor(en) / Beteiligte

• Dave, Sandeep S
• Wright, George
• Tan, Bruce
• Rosenwald, Andreas
• Gascoyne, Randy D
• Chan, Wing C
• Fisher, Richard I
• Braziel, Rita M
• Rimsza, Lisa M
• Grogan, Thomas M
• Miller, Thomas P
• LeBlanc, Michael
• Greiner, Timothy C
• Weisenburger, Dennis D
• Lynch, James C
• Vose, Julie
• Armitage, James O
• Smeland, Erlend B
• Kvaloy, Stein
• Holte, Harald
• Delabie, Jan
• Connors, Joseph M
• Lansdorp, Peter M
• Ouyang, Qin
• Lister, T. Andrew
• Davies, Andrew J
• Norton, Andrew J
• Muller-Hermelink, H. Konrad
• Ott, German
• Campo, Elias
• Montserrat, Emilio
• Wilson, Wyndham H
• Jaffe, Elaine S
• Simon, Richard
• Yang, Liming
• Powell, John
• Zhao, Hong
• Goldschmidt, Neta
• Chiorazzi, Michael
• Staudt, Louis M

Titel

Prediction of Survival in Follicular Lymphoma Based on Molecular Features of Tumor-Infiltrating Immune Cells

Ist Teil von

• The New England journal of medicine, 2004-11, Vol.351 (21), p.2159-2169

Ort / Verlag

Boston, MA: Massachusetts Medical Society

Erscheinungsjahr

2004

Quelle

MEDLINE

Beschreibungen/Notizen

• Patients with follicular lymphoma may survive for periods ranging from less than a year to several decades. In this study, DNA-microarray analysis of gene expression in specimens of follicular lymphoma showed that two genetic signatures predicted the length of survival with a high degree of accuracy. Surprisingly, one signature consisted of genes that are typically expressed in normal T cells, and the other consisted of genes expressed in monocytes and dendritic cells. DNA-microarray analysis of gene expression in specimens of follicular lymphoma showed that two genetic signatures predicted survival with a high degree of accuracy. Follicular lymphoma is the second most common form of non-Hodgkin's lymphoma, accounting for about 22 percent of all cases. 1 The clinical course of follicular lymphoma is variable: in some patients the disease is indolent and slowly progressive over a period of many years, with waxing and waning lymphadenopathy, whereas in others the disease progresses rapidly, often with transformation to aggressive lymphoma and early death. 2 , 3 Management includes observation, chemotherapy, hematopoietic stem-cell transplantation, and immunologic therapies based on antibodies to B cells 4 – 7 or idiotype vaccines. 8 – 10 There is no conclusive evidence that any of these approaches offers a clinically significant . . .